Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naive HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort

The ATHENA National ObservationalCohort Study, Astrid Oude Lashof, Selwyn Lowe, Dirk Posthouwer

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Web of Science)

Abstract

ObjectivesLamivudine (3TC) and emtricitabine (FTC) are considered interchangeable in recommended tenofovir disoproxil-fumarate (TDF)-containing combination antiretroviral therapies (cARTs). This statement of equivalence has not been systematically studied. We compared the treatment responses to 3TC and FTC combined with TDF in boosted protease inhibitor (PI)-based cART for HIV-1-infected patients.

MethodsAn observational study in the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort was carried out between 2002 and 2013. Virological failure rates, time to HIV RNA suppression <400 copies/mL, and time to treatment failure were analysed using multivariable logistic regression and Cox proportional hazard models. Sensitivity analyses included propensity score-adjusted models.

ResultsA total of 1582 ART-naive HIV-1-infected patients initiated 3TC or FTC with TDF and ritonavir-boosted darunavir (29.6%), atazanavir (41.5%), lopinavir (27.1%) or another PI (1.8%). Week 48 virological failure rates on 3TC and FTC were comparable (8.9% and 5.6%, respectively; P = 0.208). The multivariable adjusted odds ratio of virological failure when using 3TC instead of FTC with TDF in PI-based cART was 0.75 [95% confidence interval (CI) 0.32-1.79; P = 0.51]. Propensity score-adjusted models showed comparable results. The adjusted hazard ratio (HR) for treatment failure of 3TC compared with FTC was 1.15 (95% CI 0.58-2.27) within 240 weeks after cART initiation. The time to two consecutive HIV RNA measurements <400 copies/mL within 48 weeks (HR 0.94; 95% CI 0.78-1.16) and the time to treatment failure after suppression <400 copies/mL (HR 0.94; 95% CI 0.36-2.50) were not significantly influenced by the use of 3TC in TDF/PI-containing cART.

ConclusionsThe virological responses were not significantly different in treatment-naive HIV-1-infected patients starting either 3TC/TDF or FTC/TDF and a ritonavir-boosted PI.

Original languageEnglish
Pages (from-to)571-580
Number of pages10
JournalHIV Medicine
Volume17
Issue number8
DOIs
Publication statusPublished - Sep 2016

Keywords

  • HIV-1
  • antiretroviral therapy
  • boosted protease inhibitors
  • emtricitabine
  • lamivudine
  • ANTIRETROVIRAL-NAIVE
  • ABACAVIR-LAMIVUDINE
  • ONCE-DAILY DOLUTEGRAVIR
  • SUPPRESSED PATIENTS
  • REVERSE-TRANSCRIPTASE
  • INITIAL TREATMENT
  • RESISTANCE PROFILES
  • MULTICENTER TRIAL
  • CONTAINING REGIMENS
  • HIV-1 INFECTION

Cite this